# Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects

> **NCT04873570** · PHASE1 · COMPLETED · sponsor: **University of Karachi** · enrollment: 38 (actual)

## Conditions studied

- Healthy Individuals
- Bioequivalence Study

## Interventions

- **DRUG:** Moxifloxacin 400mg

## Key facts

- **NCT ID:** NCT04873570
- **Lead sponsor:** University of Karachi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-28
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-06-10
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-09-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04873570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04873570, "Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04873570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*